{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:50:53Z","timestamp":1777517453305,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1757-2215-7-38","type":"journal-article","created":{"date-parts":[[2014,4,9]],"date-time":"2014-04-09T03:03:18Z","timestamp":1397012598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer"],"prefix":"10.1186","volume":"7","author":[{"given":"Hiroshi","family":"Kawaguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Terai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Takai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoe","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Ashihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Tsunetoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Kanemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Ohmichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,9]]},"reference":[{"key":"320_CR1","first-page":"S5-2","volume":"24","author":"CJ Dunton","year":"1997","unstructured":"Dunton CJ: New options for the treatment of advanced ovarian cancer. Semin Oncol 1997, 24: S5\u20132-S5\u201311.","journal-title":"Semin Oncol"},{"key":"320_CR2","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","volume":"15","author":"W ten Bokkel Huinink","year":"1997","unstructured":"ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmstr\u00f6m H, Coleman R, Fields SC, Heron JF: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997, 15: 2183\u20132193.","journal-title":"J Clin Oncol"},{"key":"320_CR3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","volume":"16","author":"PG Rose","year":"1998","unstructured":"Rose PG, Blessing JA, Mayer AR, Homesley HD: Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998, 16: 405\u2013410.","journal-title":"J Clin Oncol"},{"key":"320_CR4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1006\/gyno.1998.5065","volume":"70","author":"M Markman","year":"1998","unstructured":"Markman M, Kennedy A, Sutton G, Hurteau J, Webster K, Peterson G, Kulp B, Belinson J: Phase II trial of single agent ifosfamide\/mesna in patients with platinum\/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. Gynecol Oncol 1998, 70: 272\u2013274. 10.1006\/gyno.1998.5065","journal-title":"Gynecol Oncol"},{"key":"320_CR5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1006\/gyno.1998.5016","volume":"69","author":"M Markman","year":"1998","unstructured":"Markman M, Blessing JA, Moore D, Ball H, Lentz SS: Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 1998, 69: 226\u2013229. 10.1006\/gyno.1998.5016","journal-title":"Gynecol Oncol"},{"key":"320_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1006\/gyno.1996.0284","volume":"63","author":"JD Shapiro","year":"1996","unstructured":"Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, Toner GC: Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996, 63: 89\u201393. 10.1006\/gyno.1996.0284","journal-title":"Gynecol Oncol"},{"key":"320_CR7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1006\/gyno.1998.5130","volume":"70","author":"DM Gershenson","year":"1998","unstructured":"Gershenson DM, Burke TW, Morris M, Bast RC, Guaspari A, Hohneker J, Wharton JT: A phase I study of a daily \u00d73 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gynecol Oncol 1998, 70: 404\u2013409. 10.1006\/gyno.1998.5130","journal-title":"Gynecol Oncol"},{"key":"320_CR8","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/0959-8049(95)00361-L","volume":"31","author":"SB Kaye","year":"1995","unstructured":"Kaye SB, Piccart M, Aapro M, Kavanagh J: Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center. Eur J Cancer 1995, 31: S14-S17.","journal-title":"Eur J Cancer"},{"key":"320_CR9","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","volume":"88","author":"T Sugiyama","year":"2000","unstructured":"Sugiyama T, Kamura T, Kigawa J, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K: Clinical characteristics of clear cell carcinoma of the ovary. Cancer 2000, 88: 2584\u20132589. 10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","journal-title":"Cancer"},{"key":"320_CR10","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1349-7006.2008.00747.x","volume":"99","author":"H Itamochi","year":"2008","unstructured":"Itamochi H, Kigawa J, Terakawa N: Mechanism of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008, 99: 653\u2013658. 10.1111\/j.1349-7006.2008.00747.x","journal-title":"Cancer Sci"},{"key":"320_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ygyno.2009.02.010","volume":"113","author":"M Shimada","year":"2009","unstructured":"Shimada M, Kigawa J, Ohishi Y, Yasuda M, Suzuki M, Hiura M, Nishimura R, Tabata T, Sugiyama T, Kaku T: Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol 2009, 113: 331\u2013334. 10.1016\/j.ygyno.2009.02.010","journal-title":"Gynecol Oncol"},{"key":"320_CR12","first-page":"5988","volume":"60","author":"J Hayakawa","year":"2000","unstructured":"Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, Adachi K, Tasaka K, Kanzaki T, Murata Y: Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 2000, 60: 5988\u20135994.","journal-title":"Cancer Res"},{"key":"320_CR13","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1210\/en.2003-1199","volume":"145","author":"E Arimoto-Ishida","year":"2004","unstructured":"Arimoto-Ishida E, Ohmichi M, Mabuchi S, Takahashi T, Ohshima C, Hayakawa J, Kimura A, Takahashi K, Nishio Y, Sakata M, Kurachi H, Tasaka K, Murata Y: Inhibition of phosphorylation of a forkhead transcription factor sensitizes human ovarian cancer cells to cisplatin. Endocrinology 2004, 145: 2014\u20132022. 10.1210\/en.2003-1199","journal-title":"Endocrinology"},{"key":"320_CR14","doi-asserted-by":"publisher","first-page":"33490","DOI":"10.1074\/jbc.M204042200","volume":"277","author":"S Mabuchi","year":"2002","unstructured":"Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto-Ishida E, Nakatsuji Y, Tasaka K, Murata Y: Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 2002, 277: 33490\u201333500. 10.1074\/jbc.M204042200","journal-title":"J Biol Chem"},{"key":"320_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL: The phosphatidylinostitol 3-kinase Akt pathway in human cancer. Nat Rev Cancer 2002, 2: 489\u2013501. 10.1038\/nrc839","journal-title":"Nat Rev Cancer"},{"key":"320_CR16","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.4161\/cbt.10.11.13443","volume":"10","author":"S Tsunetoh","year":"2010","unstructured":"Tsunetoh S, Terai Y, Sasaki H, Tanabe A, Tanaka Y, Sekijima T, Fujioka S, Kawaguchi H, Kanemura M, Yamashita Y, Ohmichi M: Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers. Cancer Biol Ther 2010, 10: 1137\u20131146. 10.4161\/cbt.10.11.13443","journal-title":"Cancer Biol Ther"},{"key":"320_CR17","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/jnci\/86.20.1530","volume":"86","author":"B Lund","year":"1994","unstructured":"Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP: Phase II study of gemcitabine (2\u2032,2\u2032-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994, 86: 1530\u20131533. 10.1093\/jnci\/86.20.1530","journal-title":"J Natl Cancer Inst"},{"key":"320_CR18","first-page":"521","volume":"2","author":"AM Bergman","year":"1996","unstructured":"Bergman AM, van Ruiz Haperen VW, Veerman G, Kuiper CM, Peters GJ: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996, 2: 521\u2013530.","journal-title":"Clin Cancer Res"},{"key":"320_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1006\/gyno.2002.6855","volume":"88","author":"RA Nagourney","year":"2003","unstructured":"Nagourney RA, Brewer CA, Radecki S, Kidder WA, Sommers BL, Evans SS, Minor DR, DiSaia PJ: Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol 2003, 88: 35\u201339. 10.1006\/gyno.2002.6855","journal-title":"Gynecol Oncol"},{"key":"320_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1006\/gyno.2002.6850","volume":"88","author":"PG Rose","year":"2003","unstructured":"Rose PG, Mossbruger K, Fusco N, Smrekar M, Eaton S, Rodriguez M: Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 2003, 88: 17\u201321. 10.1006\/gyno.2002.6850","journal-title":"Gynecol Oncol"},{"key":"320_CR21","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1158\/1078-0432.CCR-03-0488","volume":"10","author":"K Yokoi","year":"2004","unstructured":"Yokoi K, Fidler IJ: Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 2004, 10: 2299\u20132306. 10.1158\/1078-0432.CCR-03-0488","journal-title":"Clin Cancer Res"},{"key":"320_CR22","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/sim.3005","volume":"27","author":"JC Boik","year":"2008","unstructured":"Boik JC, Newman RA, Boik RJ: Quantifying synergism\/antagonism using nonlinear mixed-effects modeling: a simulation study. Stat Med 2008, 27: 1040\u20131061. 10.1002\/sim.3005","journal-title":"Stat Med"},{"key":"320_CR23","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/371346a0","volume":"371","author":"YA Lazebnik","year":"1994","unstructured":"Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC: Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994, 371: 346\u2013347. 10.1038\/371346a0","journal-title":"Nature"},{"issue":"Suppl","key":"320_CR24","first-page":"140","volume":"14","author":"P Roszkowski","year":"1993","unstructured":"Roszkowski P, Wronkowski Z, Szamborski J, Romejko M: Evaluation of selected prognostic factors in ovarian cancer. Eur J Gynaecol Oncol 1993,14(Suppl):140\u2013145.","journal-title":"Eur J Gynaecol Oncol"},{"key":"320_CR25","first-page":"850","volume":"57","author":"SW Johnson","year":"1997","unstructured":"Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC: Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 1997, 57: 850\u2013856.","journal-title":"Cancer Res"},{"key":"320_CR26","first-page":"5713","volume":"48","author":"H Masuda","year":"1988","unstructured":"Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M, Hamilton TC: Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 1988, 48: 5713\u20135716.","journal-title":"Cancer Res"},{"key":"320_CR27","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/cncr.2820710224","volume":"71","author":"SW Johnson","year":"1993","unstructured":"Johnson SW, Ozols RF, Hamilton TC: Mechanisms of drug resistance in ovarian cancer. Cancer 1993, 71: 644\u2013649.","journal-title":"Cancer"},{"key":"320_CR28","first-page":"72","volume":"4","author":"GJ Peters","year":"1995","unstructured":"Peters GJ, Bergman AM, Veerman G, van Ruiz Haperen VW, Kuiper CM, Braakhuis BJ: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995, 4: 72\u201379.","journal-title":"Semin Oncol"},{"key":"320_CR29","doi-asserted-by":"publisher","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","volume":"22","author":"Z Siddik","year":"2003","unstructured":"Siddik Z: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22: 7265\u20137279. 10.1038\/sj.onc.1206933","journal-title":"Oncogene"},{"key":"320_CR30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S1368-7646(02)00003-1","volume":"5","author":"JQ Cheng","year":"2002","unstructured":"Cheng JQ, Jiang X, Fraser M, Li M, Dan HC, Sun M, Tsang BK: Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase\/Akt pathway. Drug Resist Updat 2002, 5: 131\u2013146. 10.1016\/S1368-7646(02)00003-1","journal-title":"Drug Resist Updat"},{"key":"320_CR31","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1124\/mol.63.4.862","volume":"63","author":"MA Moufarij","year":"2003","unstructured":"Moufarij MA, Phillips DR, Culliname C: Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines. Mol Pharmacol 2003, 63: 862\u2013869. 10.1124\/mol.63.4.862","journal-title":"Mol Pharmacol"},{"key":"320_CR32","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.1158\/1078-0432.CCR-10-0832","volume":"16","author":"JA Ledermann","year":"2010","unstructured":"Ledermann JA, Gabra H, Jayson GC, Spanswick VJ, Rustin GJ, Jitlal M, James LE, Hartley JA: Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer. Clin Cancer Res 2010, 16: 4899\u20134905. 10.1158\/1078-0432.CCR-10-0832","journal-title":"Clin Cancer Res"},{"key":"320_CR33","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ygyno.2006.03.018","volume":"103","author":"CA Brewer","year":"2006","unstructured":"Brewer CA, Blessing JA, Nagourney RA, Morgan M, Hanjani P: Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006, 103: 446\u2013450. 10.1016\/j.ygyno.2006.03.018","journal-title":"Gynecol Oncol"},{"key":"320_CR34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1023\/B:DRUG.0000036690.14585.a3","volume":"22","author":"D Tewari","year":"2004","unstructured":"Tewari D, Monk BJ, Hunter M, Falkner CA, Burger RA: Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma. Invest New Drugs 2004, 22: 475\u2013480.","journal-title":"Invest New Drugs"},{"key":"320_CR35","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ygyno.2006.09.006","volume":"104","author":"G Bozas","year":"2007","unstructured":"Bozas G, Bamias A, Koutsoukou V, Efstathiou E, Gika D, Papadimitriou CA, Dimopoulos MA: Biweekly gemcitabine and cisplatin in platinum-resistant\/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynecol Oncol 2007, 104: 580\u2013585. 10.1016\/j.ygyno.2006.09.006","journal-title":"Gynecol Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1757-2215-7-38.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T12:42:33Z","timestamp":1630586553000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/1757-2215-7-38"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,9]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["320"],"URL":"https:\/\/doi.org\/10.1186\/1757-2215-7-38","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,9]]},"assertion":[{"value":"10 October 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"38"}}